Glenmark Pharmaceuticals Ltd

Glenmark Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Glenmark Pharmaceuticals Ltd

₹ 2,157 0.00%
16 Jun - close price
glenmarkpharma.com BSE: 532296 NSE: GLENMARK
About

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]

Key Points

Leadership[1]

<h1>14th largest and fastest growing in the Indian market</h1> <h1>15th largest generic company by prescriptions filled in the USA</h1> <h1>5th largest Indian generic co. in Europe.</h1>
Website BSE NSE
  • Market Cap ₹ 60,862 Cr.
  • Current Price ₹ 2,157
  • High / Low ₹ 2,474 / 1,612
  • Stock P/E 20.6
  • Book Value ₹ 372
  • Dividend Yield 0.12 %
  • ROCE 39.8 %
  • ROE 30.5 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 25.7% CAGR over last 5 years

Cons

  • The company has delivered a poor sales growth of 9.19% over past five years.
  • Company has a low return on equity of -0.77% over last 3 years.
  • Debtor days have increased from 85.2 to 107 days.
  • Working capital days have increased from 41.2 days to 80.5 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty Pharma Nifty Midcap 100

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
3,001 3,036 3,207 2,507 3,063 3,244 3,434 3,388 3,256 3,264 6,047 3,901 3,771
2,603 2,599 2,745 2,715 2,559 2,656 2,832 2,787 2,695 2,684 3,687 3,031 3,008
Operating Profit 398 437 462 -209 504 588 602 600 561 581 2,360 870 763
OPM % 13% 14% 14% -8% 16% 18% 18% 18% 17% 18% 39% 22% 20%
-696 -32 -205 87 351 31 39 31 -361 -297 -1,184 -140 -184
Interest 109 112 121 134 149 40 48 52 67 58 66 41 43
Depreciation 135 142 141 147 151 118 120 123 125 130 141 154 148
Profit before tax -542 151 -6 -403 555 462 473 456 8 96 967 534 388
Tax % -26% -14% 997% -18% 319% 26% 25% 24% 45% 51% 37% 24% 22%
-403 173 -62 -331 -1,214 340 354 348 4 47 610 403 301
EPS in Rs -15.18 5.31 -2.90 -12.45 -43.17 12.06 12.55 12.33 0.16 1.66 21.63 14.29 10.68
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
6,563 7,562 9,079 9,074 9,865 10,641 10,944 12,305 11,583 11,813 13,322 16,983
5,348 6,125 7,043 7,457 8,280 8,942 8,860 9,978 9,948 10,618 10,970 12,410
Operating Profit 1,214 1,437 2,037 1,617 1,586 1,699 2,084 2,327 1,635 1,195 2,351 4,572
OPM % 18% 19% 22% 18% 16% 16% 19% 19% 14% 10% 18% 27%
-180 20 -44 89 375 191 95 -101 -10 336 -259 -1,805
Interest 190 179 237 286 335 377 353 298 349 516 207 209
Depreciation 300 234 264 302 326 417 444 487 569 582 486 573
Profit before tax 544 1,044 1,491 1,119 1,301 1,096 1,382 1,441 707 434 1,399 1,985
Tax % 61% 29% 26% 28% 29% 29% 30% 31% 47% 430% 25% 31%
209 743 1,109 804 925 776 970 994 377 -1,434 1,047 1,362
EPS in Rs 7.72 26.33 39.29 28.49 32.78 27.50 34.38 33.37 10.53 -53.22 37.11 48.26
Dividend Payout % 26% 8% 5% 7% 6% 9% 7% 7% 24% -5% 7% 5%
Compounded Sales Growth
10 Years: 8%
5 Years: 9%
3 Years: 14%
TTM: 27%
Compounded Profit Growth
10 Years: 15%
5 Years: 26%
3 Years: 76%
TTM: 124%
Stock Price CAGR
10 Years: 11%
5 Years: 27%
3 Years: 50%
1 Year: 30%
Return on Equity
10 Years: 8%
5 Years: 3%
3 Years: -1%
Last Year: 30%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 27 28 28 28 28 28 28 28 28 28 28 28
Reserves 1,756 3,601 4,464 5,135 5,577 6,042 7,036 9,058 9,446 7,820 8,821 10,484
3,800 3,988 4,724 4,639 4,449 4,869 4,986 3,962 4,608 1,231 2,473 594
2,726 2,575 2,548 2,793 3,235 3,729 3,524 4,003 5,289 5,279 4,669 8,802
Total Liabilities 8,309 10,193 11,764 12,595 13,289 14,668 15,575 17,052 19,371 14,358 15,991 19,908
2,015 2,594 2,755 3,030 3,670 5,029 5,129 5,887 5,422 4,210 4,487 6,396
CWIP 477 543 708 1,122 1,399 1,222 1,382 1,010 1,190 662 835 428
Investments 17 17 16 15 30 25 25 50 45 790 56 42
5,799 7,039 8,285 8,429 8,190 8,393 9,040 10,105 12,715 8,697 10,613 13,042
Total Assets 8,309 10,193 11,764 12,595 13,289 14,668 15,575 17,052 19,371 14,358 15,991 19,908

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
482 345 657 1,648 1,324 1,392 1,131 1,109 625 -265 -828 3,445
-712 -950 -1,001 -1,003 -883 -774 -662 -316 -515 4,387 58 -1,283
199 699 543 -468 -739 -445 -442 -520 -77 -3,906 787 -2,709
Net Cash Flow -31 93 199 177 -297 174 28 272 32 215 17 -547
Free Cash Flow -56 -544 -76 625 712 616 456 320 75 -1,162 -1,575 2,090
CFO/OP 66% 57% 67% 124% 111% 109% 79% 72% 77% 65% -6% 92%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 140 120 97 94 81 83 86 92 115 57 92 107
Inventory Days 247 249 299 244 244 211 230 208 203 208 254 264
Days Payable 379 308 243 225 241 210 226 190 172 210 216 288
Cash Conversion Cycle 8 61 152 113 85 84 90 110 147 56 129 83
Working Capital Days 47 51 125 99 64 54 67 65 141 -2 44 81
ROCE % 16% 19% 21% 15% 15% 14% 15% 16% 10% 12% 19% 40%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
ANDA Approvals (Annual)
Number

Log in to view insights

Please log in to see hidden values.

Login
ANDA Pending Approval
Number
Manufacturing Facilities
Number
US Portfolio (Authorized Generic Products)
Number
India Dealers/Distributors Count
Number
Market Share - India Cardiac Segment
%
Market Share - India Dermatology Segment
%
R&D Spend (as % of Sales)
%
Patents Granted (Cumulative)
Number
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.64% 46.64% 46.65% 46.65%
25.51% 24.79% 23.71% 21.38% 20.98% 23.05% 23.51% 23.15% 20.62% 20.73% 19.20% 20.35%
9.10% 10.31% 10.92% 13.36% 13.93% 13.21% 13.85% 14.60% 17.64% 18.61% 20.09% 19.28%
0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04%
18.70% 18.21% 18.70% 18.58% 18.42% 17.06% 15.96% 15.56% 15.05% 13.97% 14.02% 13.70%
No. of Shareholders 2,36,9082,32,6852,09,9311,99,4511,92,6301,93,9491,95,0591,92,7241,90,2101,98,7892,01,5841,96,105

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls